Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused by a disease known as MASH.

By Sriparna Roy (Reuters) -Akero Therapeutics shares gained 106% before the bell on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse scarring of the organ without worsening the condition in a keenly awaited mid-stage trial.

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the breakthrough Phase 2b SYMMETRY data.